Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

NCT03461757 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03461757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03461757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 27, 2018
Completion date
October 15, 2018
Enrollment
1,811 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, with or without aura